Log in to access personalized features
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information. Prices might be delayed by a few minutes.
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Indogulf Cropsciences Ltd. is broadening its export footprint through a 44 metric tonne (MT) repeat order from Venezuela after a 95 MT Nutriexx export, one Thailand formulation registration and planned Brazilian trials. Indogulf reports presence in more than 36 countries and more than 140 active overseas business partners.
Know Indogulf Cropsciences inside out
Results, valuation, peers and who's buying, in one view.
Indogulf is targeting geographic diversification across Latin America, Africa, Southeast Asia and the Middle East. Its global-presence disclosure lists more than 36 countries and more than 140 active overseas business partners, while naming markets including Venezuela, Morocco, Egypt, Nigeria, Kenya, Sri Lanka, Taiwan and Australia.
The FY26 export update identifies Venezuela, Thailand, Sri Lanka and Brazil as markets at different stages of development. Indogulf says global customers are increasingly preferring reliable and compliant Indian suppliers as part of a shift away from China dependence, while its stated export strategy also focuses on fertilizers and biostimulants alongside crop-protection products.
The Venezuela development is Indogulf's most specific disclosed export milestone because a 95 MT Nutriexx export was followed by a 44 MT repeat order received “last month” in the presentation. The repeat order is 51 MT below the initial export volume, but it represents a second stated order for the same named product.
Nutriexx is the only product for which the presentation provides both a completed export volume and a subsequent order volume. Indogulf does not disclose the rupee value of either the 95 MT export or the 44 MT order, nor does it state whether the repeat order has been delivered.
The Venezuela result differs from the company's regulatory and trial-stage developments in Thailand, Sri Lanka and Brazil. It provides evidence of a completed export followed by another order, whereas the other disclosed market actions concern product registration, import permission or field trials.
Indogulf has obtained one formulation registration in Thailand for Spiromesifen 24% suspension concentrate, weight by volume (SC w/v). The presentation identifies the registration as a regulatory achievement, but does not disclose a Thai sales order, shipment volume, launch date or revenue contribution for Spiromesifen 24% SC w/v.
In Sri Lanka, Indogulf reports positive field-trial results and import permission for Indoapache. That places Indoapache at a later market-access stage than the two additional combination formulations for which the company says field trials have commenced in Sri Lanka.
Those two Sri Lankan trial products are Carbendazim 12% plus Mancozeb 63% wettable powder (WP), and Thiamethoxam 17.5% plus Chlorantraniliprole 8.8% SC. The distinction matters because import permission is disclosed for Indoapache, while the two combinations remain in the field-trial process.
The disclosed products also sit alongside a business mix in which fungicides represented 57% in Q2FY27, herbicides 28%, insecticides 15% and others 1.0%. Indogulf does not provide an export-only product mix, so the presentation does not show how Thailand or Sri Lanka sales, if any, are distributed across these categories.
Indogulf has decided to initiate field trials in Brazil for Empire and Indoapache. It also says it will enter into an agreement with a Brazilian contract research organisation (CRO) to support those trial activities, making Brazil a planned validation initiative rather than a disclosed commercial market entry.
Brazil and Venezuela both form part of Indogulf's Latin American development, but their milestones are different. Venezuela has a completed 95 MT Nutriexx export and a 44 MT repeat order, while Brazil is at the intended field-trial stage for two named products, Empire and Indoapache.
The presentation does not provide a trial timetable, CRO name, registration-filing date, target sales volume or expected revenue for Brazil. The commercial outcome therefore depends on the planned field trials and subsequent regulatory and market-access steps that are not detailed in the FY26 update.
Indogulf says its regulatory infrastructure supports global scalability, but the presentation reports two registration totals. The export-growth driver section cites 189 registrations, while the regulatory table reports 162 total registrations, including 128 valid registrations and seven under renewal.
The disclosed difference between 189 and 162 is 27 registrations, and the presentation does not reconcile the two totals or define whether they use different scopes. It also does not specify the countries, products or registration categories included in either the 189 figure or the 162 total.
Indogulf's export strategy identifies fertilizers and biostimulants as areas of rising contribution intended to strengthen portfolio quality and margins. However, the named FY26 overseas milestones cover Nutriexx in Venezuela, Spiromesifen 24% SC w/v in Thailand, Indoapache in Sri Lanka and Brazil, and two Sri Lankan crop-protection combinations.
The company describes crop protection, plant nutrients and biologicals as its principal product verticals. In H1 FY27, crop protection accounted for 85% of revenue share, compared with 5% for plant nutrients and 6% for biologicals, although Indogulf does not disclose comparable export revenue by product category or country.
Indogulf's disclosed export expansion is supported most directly by the 95 MT Nutriexx export to Venezuela and the subsequent 44 MT repeat order. Thailand adds one Spiromesifen 24% SC w/v registration, while Sri Lanka adds Indoapache import permission and trials of two combination formulations, showing that the company is pursuing several markets through different commercial and regulatory routes.
The next points to watch are delivery or revenue disclosure for Venezuela's 44 MT order, market activity following Thailand's registration, and results from the Sri Lankan and planned Brazilian trials for Empire and Indoapache. Management's ability to clarify the difference between the stated 189 registrations and the table's 162 total registrations would also provide greater visibility on the regulatory base behind the expansion plan.
Loading comments…